January 30, 2018 / 1:29 PM / in 13 minutes BRIEF-Puma Biotechnology And Medison Pharma Enter Licensing Agreement To Commercialize Nerlynx In Israel Reuters Staff 1 Min Read 
Jan 30 (Reuters) - Puma Biotechnology Inc: 
* PUMA BIOTECHNOLOGY AND MEDISON PHARMA ENTER INTO EXCLUSIVE LICENSING AGREEMENT TO COMMERCIALIZE NERLYNXÂ® (NERATINIB) IN ISRAEL 
* PUMA BIOTECHNOLOGY INC - CO, MEDISON PHARMA LTD ENTERED INTO EXCLUSIVE AGREEMENT UNDER WHICH MEDISON WILL COMMERCIALIZE NERLYNX IN ISRAEL 
* PUMA BIOTECHNOLOGY SAYS WILL RECEIVE UPFRONT, MILESTONE PAYMENTS THROUGHOUT AGREEMENT TERM, & DOUBLE DIGIT ROYALTIES ON NERLYNX SALES IN ISRAEL 
* PUMA BIOTECHNOLOGY SAYS EXPECT TO RECEIVE REGULATORY APPROVAL FOR NERLYNX IN ISRAEL DURING H1 2019 Source text for Eikon: Further company coverage: